

Michael S Lawrence

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3021339/publications.pdf>

Version: 2024-02-01

57
papers

23,298
citations

126907

33
h-index

161849

54
g-index

61
all docs

61
docs citations

61
times ranked

40118
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational heterogeneity in cancer and the search for new cancer-associated genes. <i>Nature</i> , 2013, 499, 214-218.	27.8	4,761
2	Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. <i>Nature Biotechnology</i> , 2013, 31, 213-219.	17.5	3,934
3	Discovery and saturation analysis of cancer genes across 21 tumour types. <i>Nature</i> , 2014, 505, 495-501.	27.8	2,586
4	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. <i>Cell</i> , 2018, 173, 291-304.e6.	28.9	1,718
5	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , 2018, 173, 371-385.e18.	28.9	1,670
6	An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. <i>Nature Genetics</i> , 2013, 45, 970-976.	21.4	1,023
7	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. <i>Nature Genetics</i> , 2016, 48, 607-616.	21.4	933
8	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	9.4	821
9	Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. <i>Nature Genetics</i> , 2013, 45, 478-486.	21.4	671
10	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. <i>Cell Systems</i> , 2018, 6, 271-281.e7.	6.2	605
11	Supercharging Proteins Can Impart Unusual Resilience. <i>Journal of the American Chemical Society</i> , 2007, 129, 10110-10112.	13.7	438
12	A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. <i>Nature Genetics</i> , 2017, 49, 1476-1486.	21.4	427
13	Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. <i>Cell</i> , 2019, 178, 160-175.e27.	28.9	367
14	Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair. <i>Cell</i> , 2016, 164, 538-549.	28.9	363
15	Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. <i>Nature Genetics</i> , 2017, 49, 10-16.	21.4	307
16	<code>VariantAnnotation</code> : a <code>Bioconductor</code> package for exploration and annotation of genetic variants. <i>Bioinformatics</i> , 2014, 30, 2076-2078.	4.1	293
17	Recurrent and functional regulatory mutations in breast cancer. <i>Nature</i> , 2017, 547, 55-60.	27.8	269
18	Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features. <i>Science</i> , 2019, 364, .	12.6	229

#	ARTICLE	IF	CITATIONS
19	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer. <i>Cancer Discovery</i> , 2018, 8, 714-729.	9.4	228
20	Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 1372-1387.	9.4	158
21	SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. <i>Nature Medicine</i> , 2018, 24, 512-517.	30.7	155
22	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2467-2472.	7.1	131
23	MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2535-2545.	7.0	127
24	Analysis of somatic microsatellite indels identifies driver events in human tumors. <i>Nature Biotechnology</i> , 2017, 35, 951-959.	17.5	106
25	APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition. <i>Cancer Research</i> , 2017, 77, 4567-4578.	0.9	104
26	A Code of Mono-phosphorylation Modulates the Function of RB. <i>Molecular Cell</i> , 2019, 73, 985-1000.e6.	9.7	98
27	Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. <i>Cell Chemical Biology</i> , 2021, 28, 503-514.e12.	5.2	80
28	Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots. <i>Nature Communications</i> , 2020, 11, 2971.	12.8	71
29	Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26835-26845.	7.1	69
30	An extended APOBEC3A mutation signature in cancer. <i>Nature Communications</i> , 2021, 12, 1602.	12.8	69
31	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2899-2909.	7.0	62
32	Passenger Hotspot Mutations in Cancer. <i>Cancer Cell</i> , 2019, 36, 288-301.e14.	16.8	59
33	Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. <i>Npj Precision Oncology</i> , 2020, 4, 21.	5.4	36
34	Cross-talk between Lysine-Modifying Enzymes Controls Site-Specific DNA Amplifications. <i>Cell</i> , 2018, 174, 803-817.e16.	28.9	34
35	Histone Lysine Methylation Dynamics Control <i>EGFR</i> DNA Copy-Number Amplification. <i>Cancer Discovery</i> , 2020, 10, 306-325.	9.4	31
36	Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of <i>BRCA2</i> mutation carriers. <i>Science Advances</i> , 2020, 6, eaay2611.	10.3	27

#	ARTICLE	IF	CITATIONS
37	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. <i>Npj Precision Oncology</i> , 2019, 3, 18.	5.4	25
38	A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells. <i>Genome Biology</i> , 2020, 21, 33.	8.8	22
39	Extracellular matrix proteins regulate NK cell function in peripheral tissues. <i>Science Advances</i> , 2022, 8, eabk3327.	10.3	20
40	Genome-wide mapping of regions preferentially targeted by the human DNA-cytosine deaminase APOBEC3A using uracil-DNA pulldown and sequencing. <i>Journal of Biological Chemistry</i> , 2019, 294, 15037-15051.	3.4	18
41	Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. <i>Modern Pathology</i> , 2021, 34, 264-279.	5.5	16
42	APOBEC Mutagenesis Is Concordant between Tumor and Viral Genomes in HPV-Positive Head and Neck Squamous Cell Carcinoma. <i>Viruses</i> , 2021, 13, 1666.	3.3	16
43	NR4A1 regulates expression of immediate early genes, suppressing replication stress in cancer. <i>Molecular Cell</i> , 2021, 81, 4041-4058.e15.	9.7	16
44	Altered biochemical specificity of G-quadruplexes with mutated tetrads. <i>Nucleic Acids Research</i> , 2016, 44, 10789-10803.	14.5	14
45	Identification of Somatic Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4852-4862.	7.0	12
46	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4883-4897.	7.0	11
47	Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer. <i>Science Advances</i> , 2022, 8, eabn1229.	10.3	9
48	GTP-Dependent Formation of Multimeric G-Quadruplexes. <i>ACS Chemical Biology</i> , 2019, 14, 1951-1963.	3.4	8
49	HPV+ oropharyngeal squamous cell carcinomas from patients with two tumors display synchrony of viral genomes yet discordant mutational profiles and signatures. <i>Carcinogenesis</i> , 2021, 42, 14-20.	2.8	8
50	Human activation-induced deaminase lacks strong replicative strand bias or preference for cytosines in hairpin loops. <i>Nucleic Acids Research</i> , 2022, 50, 5145-5157.	14.5	8
51	Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series. <i>Blood Advances</i> , 2020, 4, 1859-1866.	5.2	7
52	Redirecting T-Cells Against AML in a Multidimensional Targeting Space Using T-Cell Engaging Antibody Circuits (TEAC). <i>Blood</i> , 2019, 134, 2653-2653.	1.4	4
53	Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy. <i>Cancer Research</i> , 2022, 82, 773-784.	0.9	3
54	Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition. <i>Cancer Research</i> , 2022, 82, 1084-1097.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Abstract 1146: Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. , 2021, , .		0
56	Mutational Dynamics and Evolutionary Divergence in DLBCL: A Call for Relapse Sampling. Blood, 2019, 134, 1497-1497.	1.4	0
57	Abstract P1-07-05: Gene expression analysis of <i>HOXB13</i> -high and -low tumors reveals a dichotomous immune landscape. Cancer Research, 2022, 82, P1-07-05-P1-07-05.	0.9	0